Cisplatin urinary pharmacokinetics and nephrotoxicity: a common circadian mechanism
- PMID: 6890406
Cisplatin urinary pharmacokinetics and nephrotoxicity: a common circadian mechanism
Abstract
Renal toxicity and urinary pharmacokinetics following a nonlethal dose (5 mg/kg) of cisplatin were investigated in female F344 (Fischer) rats that were on a standardized light-dark schedule, with water freely available. Circadian timing of drug administration had a major effect on the BUN increase (P less than 0.01), the urine volume increase (P less than 0.025), and the urinary concentration of cisplatin following drug administration (P less than 0.01). Renal toxicity was positively correlated with the peak urinary concentration of cisplatin and with the area under the curve of urinary concentration over the first 20 hours after drug administration (P less than 0.01). Drug administration near the normal circadian maximum of urinary volume prior to treatment resulted in the least renal toxicity, lowest peak, and smallest area of urinary concentration of cisplatin.
Similar articles
-
Reduction of cis-diamminedichloroplatinum nephrotoxicity in rats by optimal circadian drug timing.Cancer Res. 1982 Mar;42(3):950-5. Cancer Res. 1982. PMID: 7199382
-
Circadian stage dependence of cis-diamminedichloroplatinum lethal toxicity in rats.Cancer Res. 1982 Mar;42(3):945-9. Cancer Res. 1982. PMID: 7199381
-
Amelioration of cisplatin-induced nephrotoxicity by the diuretic acetazolamide in F344 rats.Cancer Treat Rep. 1984 Jul-Aug;68(7-8):999-1004. Cancer Treat Rep. 1984. PMID: 6540145
-
cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.Clin Cancer Res. 1997 Nov;3(11):2063-74. Clin Cancer Res. 1997. PMID: 9815598
-
[Prophylactic effect of methylprednisolone on cisplatin-induced nephrotoxicity].Fukuoka Igaku Zasshi. 1995 Feb;86(2):31-9. Fukuoka Igaku Zasshi. 1995. PMID: 7729781 Japanese.
Cited by
-
Evaluation of the effect of furosemide on ultrafilterable platinum kinetics in patients treated with cis-diamminedichloroplatinum.Cancer Chemother Pharmacol. 1989;23(1):37-40. doi: 10.1007/BF00258455. Cancer Chemother Pharmacol. 1989. PMID: 2909288 Clinical Trial.
-
Circadian changes in the pharmacokinetics of oral ketoprofen.Clin Pharmacokinet. 1987 May;12(5):367-78. doi: 10.2165/00003088-198712050-00003. Clin Pharmacokinet. 1987. PMID: 3608343 Clinical Trial.
-
Urinary beta 2-microglobulin: early indicator of high dose cisdiamminedichloroplatinum nephrotoxicity? Influence of furosemide.Cancer Chemother Pharmacol. 1986;18(3):276-9. doi: 10.1007/BF00273402. Cancer Chemother Pharmacol. 1986. PMID: 3542269
-
Evaluation of the biochemical effects of CHIP in normal and tumour-bearing C3H mice.Br J Cancer. 1986 Jun;53(6):761-72. doi: 10.1038/bjc.1986.130. Br J Cancer. 1986. PMID: 3718829 Free PMC article.
-
Theoretical study of the influence of the circadian rhythm of plasma protein binding on cisplatin area under the curve.J Pharmacokinet Biopharm. 1986 Feb;14(1):79-93. doi: 10.1007/BF01059285. J Pharmacokinet Biopharm. 1986. PMID: 3746633